Inspire(US:INSP) Businesswire·2025-12-22 22:33Core Viewpoint - A class action has been filed against Inspire Medical Systems, Inc. and certain executives for alleged violations of federal securities laws during the Class Period from August 6, 2024, to August 4, 2025, related to the launch of the Inspire V device [1][2]. Group 1: Allegations and Company Background - Inspire Medical Systems is a medical device company that develops the Inspire system, an implantable neurostimulation system for treating obstructive sleep apnea, with the Inspire V model scheduled for launch in 2025 [3]. - The allegations against Inspire and its executives stem from misrepresentations regarding the launch of the Inspire V device, where they assured investors of readiness and positive feedback during the soft launch, despite knowing about critical issues such as lack of demand and reimbursement problems [4]. Group 2: Impact of Disclosures - On August 4, 2025, Inspire announced an 80% reduction in its full-year earnings per share guidance, citing headwinds that hindered customer transitions to Inspire V, including incomplete training and challenges with Medicare reimbursement codes [5]. - Following this announcement, Inspire's stock price fell by $42.04 per share, representing a decline of 32.4% [5]. Group 3: Legal Proceedings - The class action is filed on behalf of the Indiana Public Retirement System and is related to a previously filed securities class action against Inspire [2]. - Investors who purchased Inspire common stock during the Class Period have until January 5, 2026, to seek appointment as Lead Plaintiff for the Class [6].